Patents by Inventor Jacque Sauzieres

Jacque Sauzieres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
    Patent number: 11554106
    Abstract: A method of treating a subject for reducing the risk of QT space prolongation associated with the intake of a drug known to prolong QT space includes administering to the subject at least one specific inhibitor of mitochondrial ROS production selected from among anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, and administering to the subject the drug known to prolong QT space.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: January 17, 2023
    Inventors: Marc Childs, Jacque Sauzieres, Olivier Petitjean, Guillaume Petitjean, Elodie Petitjean, Grégoire Petitjean
  • PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN
    Publication number: 20210052549
    Abstract: A method of treating a subject for reducing the risk of QT space prolongation associated with the intake of a drug known to prolong QT space includes administering to the subject at least one specific inhibitor of mitochondrial ROS production selected from among anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, and administering to the subject the drug known to prolong QT space.
    Type: Application
    Filed: March 7, 2018
    Publication date: February 25, 2021
    Inventors: Marc Childs, Jacque Sauzieres, Olivier Petitjean, Guillaume Petitjean, Elodie Petitjean, Grégoire Petitjean
  • Therapeutic uses of heterologous superoxide dismutase (HSD), and method for selecting said HSD
    Patent number: 6426068
    Abstract: The invention concerns novel therapeutic uses of heterologous superoxide dismutase (HSD) for preparing medicines for treating diseases in which cell and organic degeneration is observed, and a method for selecting said HSD.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: July 30, 2002
    Assignee: Fractales Biotech
    Inventors: Bernard Dugas, Alphonse Calenda, Jacques Sauzieres, Eric Postaire
  • Pharmaceutical compositions containing a superoxide dismutase
    Patent number: 6045809
    Abstract: Novel pharmaceutical compositions that are particularly suitable for oral administration of superoxide dismutases (SODs) and that have good bioavailability and therapeutic efficacy. These compositions are made up of a combination of a superoxide dismutase and at least one lipids or proteins. The lipids are exemplified by ceramides, and the proteins are exemplified by prolamines or polymer films based on such prolamines. A pharmaceutically acceptable vehicle can also be included in the composition.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: April 4, 2000
    Assignee: Institut de Recherches Franctales
    Inventors: Eric Postaire, Corinne Regnault, Monique Rock-Arveiller, Valerie Stella, Michel Brack, Jacques Sauzieres
  • Use of 7-acyl benzoxazinones and their derivatives in treating atheromatous disorders
    Patent number: 4778792
    Abstract: The invention relates to products characterized by the general formula: ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R and X have the meanings indicated in claim 1. The invention also related to pharmaceutical compositions administrable particularly orally, containing the abovesaid compounds in association with a pharmaceutically acceptable vehicle. They are useful as medicaments.
    Type: Grant
    Filed: October 20, 1986
    Date of Patent: October 18, 1988
    Assignee: Laboratories Negma
    Inventors: Isabelle Lesieur, Charles Lespagnol, Ziaddine Moussavi, Jean-Claude Fruchart, Jacques Sauzieres, Nicole Monfilliette